Addiction Susceptibility (DRD2/OPRM1)
Prevalence: ~35 million people worldwide with substance use disorders (UNODC 2023)
Genetic variation in dopamine (DRD2/ANKK1) and opioid (OPRM1) receptor systems creates differential vulnerability to substance use disorders. Personalized pharmacotherapy guided by genotype is an emerging paradigm.
Peptide Therapeutics
DRD2-modulating neuropeptides, opioid receptor partial agonist peptides, GLP-1 agonist peptides (showing anti-addiction effects in trials), and reward-circuit-targeting therapeutic peptides.
Current Treatments
Buprenorphine (partial opioid agonist), naltrexone, methadone, disulfiram, acamprosate. Genotype-guided treatment selection is experimental.
Key Genetic Variants
Associated Genes
Primary receptor for endogenous opioid peptides (beta-endorphin, enkephalins) and opioid analgesics. Mediates analgesia, reward, respiratory depression, and physical dependence.
Explore peptide candidates for Addiction Susceptibility (DRD2/OPRM1)
Submit rs1800497, rs1799971 to PepFold. Full report with 3D structures and synthesis protocols in under 2 minutes.